Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy

Journal of Thoracic Oncology

Volumn 3, Issue 7, 2008, Pages 716-722

  Tsakiridis, Theodoros ^a,b   Cutz, Jean Claude ^a,c   Singh, Gurmit ^a,b   Hirte, Hal ^a,b   Okawara, Gordon ^a,b   Corbett, Tom ^a,b   Sur, Ranjan ^a,b   Cai, Wenjie ^b   Whelan, Tim ^a,b   Wright, James R ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Epidermal growth factor receptor; Extracellular signal regulated kinase; NSCLC; Prognostic marker; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEMCITABINE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PROTEIN KINASE B; STAT3 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; CELL PROLIFERATION; CHEMISTRY; IMMUNOBLOTTING; LUNG TUMOR; MIDDLE AGED; MORTALITY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, NON-SMALL-CELL LUNG; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 50349101588     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31817c6094     Document Type: Article

References (21)

1. MacRae R, Choy H. Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer. Curr Oncol Rep 2003;5:313-317.
2. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005;1(Suppl 12):S17-S27.
3. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947.
4. Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002;21:4032-4041.
5. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165.
6. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-2008.
7. Schlessinger J. How tyrosine kinases activate Ras. Trends Biochem Sci 1993;18:273-275.
8. Ridley AJ. Membrane ruffling and signal transduction. Bioessays 1994; 16:321-327.
9. Margolis B, Skolnik EY. Activation of Ras by receptor tyrosine kinases. J Am Soc Nephrol 1994;5:1288-1299.
10. Cline MJ, Battifora H. Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. Cancer 1987;60:2669-2674.
11. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-981.
12. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006;61:140-145.
13. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
14. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006;12:7117-7125.
15. Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol. 2007; 2(Suppl 2):S68-S76.
16. Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 2007;55:349-355.
17. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-1141.
18. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005;113:109-115.
19. Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 2007;55:115-121.
20. Vicent S, Lopez-Picazo JM, Toledo G, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004;90:1047-1052.
21. Hagan M, Wang L, Hanley JR, Park JS, Dent P. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 2000;153: 371-383.